Biotech News
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
ir.moonlaketx.com2026-05-06 15:27 EST
Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026 Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP),